Effect of platelet inhibition with cangrelor during PCI on ischaemic events

Source: New England Journal of Medicine Area: News The findings of a study evaluating whether cangrelor reduces ischaemic complications of percutaneous coronary intervention (PCI) have been presented at the meeting of the American College of Cardiology and published early online in the New England Journal of Medicine.   The authors note that thrombotic complications during PCI remain a major concern, despite advances in adjunctive pharmacotherapy. Although platelet adenosine diphosphate (ADP) P2Y12 inhibitors reduce the risk of ischaemic events, particularly stent thrombosis, only oral agents are currently available, and patients in the acute phase of cardiovascular illness may have conditions that limit drug availability. Sources of variation in the pharmacokinetic and pharmacodynamic response to clopidogrel have also been described. Glycoprotein IIb/IIIa inhibitors are effective but their effects last for hours and cannot be easily reversed.   Cangrelor is a fast-acting, rapidly reversible intravenous ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news